Offering Hope for Heart Disease
At Holy Cross Health, we are committed to helping our patients live full, healthy lives. That’s why we offer clinical research trials—to provide possibilities for today and hope for tomorrow.
We invite you to learn about a clinical cardiac research trial for which we are currently enrolling patients.
Watch the video and complete the form. We’ll be in touch.
Do you have Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy?
Elias Collado, MD, is the principal investigator for the Cytokinetics clinical trial which will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
All participants (ages 18 to 85) will receive the study drug and be followed closely for 72 weeks (8.5 months).
Not a candidate for this trial?
See more open clinical cardiac trials at Holy Cross Health.